Skip to main content
Antonio Anzueto, MD, Pulmonology, San Antonio, TX

AntonioAnzuetoMD

Pulmonology San Antonio, TX

Critical Care Medicine

Professor, Medicine, University of Texas Medical School, San Antonio

Dr. Anzueto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Anzueto's full profile

Already have an account?

  • Office

    7703 Floyd Curl Dr
    # MC7977
    San Antonio, TX 78229
    Phone+1 210-257-1400
    Fax+1 210-257-1428

Education & Training

  • University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
    University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Pulmonary Disease and Critical Care Medicine, 1989 - 1992
  • University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
    University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 1987 - 1988
  • Universidad de San Carlos FOMS
    Universidad de San Carlos FOMSClass of 1979

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1991 - 2025
  • OK State Medical License
    OK State Medical License 1989 - 1992

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Dual Phosphodiesterase Inhibitor Improved Lung Function in COPD Patients
    Dual Phosphodiesterase Inhibitor Improved Lung Function in COPD PatientsMay 24th, 2023
  • Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
    Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023May 2nd, 2023
  • Boehringer Ingelheim Welcomes New 2023 GOLD Report Positioning LAMA/LABA as the Preferred Treatment for the Majority of Patients with COPD
    Boehringer Ingelheim Welcomes New 2023 GOLD Report Positioning LAMA/LABA as the Preferred Treatment for the Majority of Patients with COPDNovember 17th, 2022
  • Join now to see all